Literature DB >> 2987867

The human urokinase-plasminogen activator gene and its promoter.

A Riccio, G Grimaldi, P Verde, G Sebastio, S Boast, F Blasi.   

Abstract

The urokinase type of plasminogen activator (uPA) is subject to regulation by hormones, phorbol esters and oncogenic transformation. This enzyme has been suggested to play a key role in processes involving cell migration and tissue remodeling, and to be essential for tumor metastasis. In order to study these processes, we have isolated the human uPA gene, and have determined its entire nucleotide sequence. The gene is organized in 11 exons and is 6.4 kb long. The 5' end of uPA mRNA has been determined by both S1 mapping and primer extension experiments. A fragment of 800 bp containing the entire 5' flanking region shows promoter activity when introduced upstream of a bacterial chloramphenicol acetyltransferase gene and introduced into human cells. The hexanucleotide sequence GGCGGG, previously found at similar regions in several viral and eukaryotic promoters and shown to be essential for promoter activity (McKnight et al. (1984) Cell, 37, 253-262), is repeated three times between the CAAT and the TATA boxes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987867      PMCID: PMC341192          DOI: 10.1093/nar/13.8.2759

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  50 in total

1.  A new method for sequencing DNA.

Authors:  A M Maxam; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

2.  Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor.

Authors:  G Salerno; P Verde; M L Nolli; A Corti; H Szöts; T Meo; J Johnson; S Bullock; G Cassani; F Blasi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

3.  Why genes in pieces?

Authors:  W Gilbert
Journal:  Nature       Date:  1978-02-09       Impact factor: 49.962

4.  Ovalbumin gene: evidence for a leader sequence in mRNA and DNA sequences at the exon-intron boundaries.

Authors:  R Breathnach; C Benoist; K O'Hare; F Gannon; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

5.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

6.  Adaptation of plasminogen activator sequences to known protease structures.

Authors:  W Strassburger; A Wollmer; J E Pitts; I D Glover; I J Tickle; T L Blundell; G J Steffens; W A Günzler; F Otting; L Flohé
Journal:  FEBS Lett       Date:  1983-07-04       Impact factor: 4.124

7.  Nerve growth factor receptors on human melanoma cells in culture.

Authors:  R N Fabricant; J E De Larco; G J Todaro
Journal:  Proc Natl Acad Sci U S A       Date:  1977-02       Impact factor: 11.205

8.  Amino-acid sequence of activation cleavage site in plasminogen: homology with "pro" part of prothrombin.

Authors:  L Sottrup-Jensen; M Zajdel; H Claeys; T E Petersen; S Magnusson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-07       Impact factor: 11.205

9.  The E1b promoter of Ad12 in mouse L tk- cells is activated by adenovirus region E1a.

Authors:  J L Bos; H C ten Wolde-Kraamwinkel
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

10.  High efficiency of replication and expression of foreign genes in SV40-transformed human fibroblasts.

Authors:  S Boast; G La Mantia; L Lania; F Blasi
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  47 in total

1.  Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase.

Authors:  K Murakami; R Sakukawa; T Ikeda; T Matsuura; S Hasumura; S Nagamori; Y Yamada; I Saiki
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

2.  Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy?

Authors:  D J Buttle; H Bramwell; A P Hollander
Journal:  Clin Mol Pathol       Date:  1995-08

3.  Tissue-type plasminogen activator in rat adrenal medulla.

Authors:  P Kristensen; D M Hougaard; L S Nielsen; K Danø
Journal:  Histochemistry       Date:  1986

4.  Enhancement of type IV collagenases by highly metastatic variants of HT1080 fibrosarcoma cells established by a transendothelial invasion system in vitro.

Authors:  T Okada; J Li; M Kodaka; H Okuno
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

5.  BamHI RFLP linked to the human urokinase gene.

Authors:  G Sebastio; A Riccio; P Verde; N Scarpato; F Blasi
Journal:  Nucleic Acids Res       Date:  1985-07-25       Impact factor: 16.971

6.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation.

Authors:  P H Quax; N Pedersen; M T Masucci; E J Weening-Verhoeff; K Danø; J H Verheijen; F Blasi
Journal:  Cell Regul       Date:  1991-10

7.  Single-nucleotide polymorphism of the urokinase-plasminogen activator gene during aging and transformation of human diploid kidney cell cultures.

Authors:  Safedin H Beqaj; David Post; Jon M Ryan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2003 Sep-Oct       Impact factor: 2.416

8.  Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.

Authors:  U Reuning; O Wilhelm; T Nishiguchi; L Guerrini; F Blasi; H Graeff; M Schmitt
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

9.  Amiloride modulates urokinase gene expression at both transcription and post-transcription levels in human colon cancer cells.

Authors:  Y Wang; J Dang; X Liang; W F Doe
Journal:  Clin Exp Metastasis       Date:  1995-05       Impact factor: 5.150

10.  The urokinase receptor is required for human monocyte chemotaxis in vitro.

Authors:  M R Gyetko; R F Todd; C C Wilkinson; R G Sitrin
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.